How Cannabinoids Could Protect the Heart from Scarring and Remodeling | Research

The takeaway

Activating CB2 receptors and blocking peripheral CB1 receptors shows particular promise for preventing harmful cardiac scarring after heart attacks and during chronic disease.

Cardiologists, cardiovascular researchers, endocannabinoid system specialists, drug development scientists

What the researchers found

Specific CB2 receptor activation and peripheral CB1 receptor blockade appear particularly promising for anti-fibrotic cardiac effects. The cardioprotective potential lies in cannabinoids' antioxidant and anti-inflammatory efficacy, which limits fibrotic progression and restores normal molecular signaling pathways.

Why it matters

Cardiac fibrosis — scarring of the heart — drives heart failure after heart attacks and during hypertension and diabetes. Current anti-fibrotic treatments are limited, making the endocannabinoid system an important new therapeutic target.

The numbers in context

Review covers cardiac remodeling across multiple conditions: post-myocardial infarction, arterial hypertension, pulmonary hypertension, and diabetes mellitus. Two receptor targets identified as most promising: CB2 activation and peripheral CB1 blockade.

How the study worked

Comprehensive narrative review describing key signaling pathways involved in cardiac fibrosis and examining the utility of cannabinoids and endocannabinoid system modulation as therapeutic interventions, synthesizing preclinical and mechanistic evidence.

What this study cannot tell us

Primarily based on preclinical evidence. The complexity of the endocannabinoid system means targeting one receptor may have unintended effects elsewhere. Clinical translation faces significant regulatory and safety hurdles.

How to read the evidence

Thorough mechanistic review synthesizing substantial preclinical evidence, but clinical data on cannabinoid cardiac therapies remains very limited.

When this study was published

Published 2026, incorporating the latest understanding of endocannabinoid system cardiac roles.

The bigger picture

Heart failure remains the leading cause of death worldwide. If cannabinoid-based therapies can prevent the fibrotic remodeling that drives cardiac decline, they could complement existing treatments for millions of patients with chronic heart conditions.

Questions still open

Can selective CB2 agonists be developed without psychoactive effects? Would peripheral CB1 blockers avoid the psychiatric side effects seen with rimonabant? How would cannabinoid therapy interact with standard cardiac medications?

Common questions

Can cannabinoids protect the heart?

Preclinical evidence suggests that targeting the endocannabinoid system — specifically activating CB2 receptors and blocking peripheral CB1 receptors — could prevent harmful cardiac scarring after heart attacks and during chronic conditions like hypertension and diabetes.

How do cannabinoids prevent heart scarring?

Cannabinoids work through their antioxidant and anti-inflammatory properties to limit the progression of fibrotic lesions in the heart and restore normal regulation of the molecular pathways that drive harmful tissue remodeling.

Read the original research

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence.

British journal of pharmacology

View on PubMed ↗Publisher’s paper ↗

Citation

Krzyżewska, Anna; Baranowska-Kuczko, Marta; Kozłowska, Hanna. (2026). The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence.. British journal of pharmacology. https://doi.org/10.1111/bph.70347